Essential hyperhidrosis in Turner syndrome

We describe two Turner patients suffering from severe essential hyperhidrosis. Since both disorders are rare (1 in 5000 live female births for Turner syndrome and approximately 1 in 1000 persons for essential hyperhidrosis), our finding of two patients with these disorders in a total of 150 essential hyperhidrosis patients may suggest that this association is more frequent in Turner syndrome than previously thought.     

一孔法胸腔镜下交感神经链切断术治疗手汗症30例临床研究

目的探讨一孔法电视胸腔镜下T3或T4交感神经链及其侧支切断术治疗手汗症的可行性。方法在全麻双腔气管插管下施行T3或T4交感神经链及其侧支切断术治疗手汗症30例。结果30例手术均获成功,术后患者手掌多汗症状消失,有效率为100％,术后掌温升高（2．5±0．8）℃。30例随访1．5-12个月,平均8月,无一例复发及严重代偿性多汗．轻度代偿性多汗1例,占3．3％0／30）。结论一孔法电视胸腔镜下]r3或T4交感神经链及其侧支切断术治疗手汗症疗效确切,创伤小,疼痛较轻,且术后代偿性多汗发生率低,程度轻微,是一种安全、有效的手术方式。     

T2-4与T3-4交感神经链切断治疗手足多汗症术后代偿性出汗比较

目的:通过比较胸腔镜下T2-4与T3-4交感神经链切断治疗手足多汗症术后代偿性出汗发生情况,探讨其发生的可能机制.方法:手足多汗症患者146例,按不同手术方式分为T2-4组(行T2-4水平交感神经链切断术,共66例)与T3-4组(行T3-4水平交感神经链切断术,共80例).比较两组术后第1日、第6个月手术效果以及代偿性出汗发生部位和严重程度.结果:术后两组手汗治愈率100％,最常见代偿性出汗部位是背部和胸部.术后第1日T2-4组代偿性出汗发生率明显高于T3-4组(39％对比21％,P＜0.05),T2-4组出现2例重度代偿性出汗,T3-4组无重度者.术后6个月T2-4组代偿性出汗发生率依然明显高于T3-4组[24％ (16/66)对比11％ (9/80),P＜0.05].T2-4组仍有1例重度代偿性出汗患者.结论:降低胸交感神经链切断位置可减少代偿性出汗发生率和严重程度,T3-4切断术是一种较为理想的手术方式.代偿性出汗可能随时间有缓解趋势.     

郑俊谦主任医师运用当归六黄汤加减治疗小儿多汗症经验

介绍了郑俊谦主任医师治疗小儿多汗症的经验.小儿多汗症一般多从虚证立论,郑老师提出小儿多汗症不仅有虚证,也有实证的观点,其病机为里热蒸腾,心肝火炽,湿热内羁,迫液外泄.临床以滋阴泻火结合御风、运脾等为治疗大法,方用当归六黄汤加减.     

The evolution of botulinum neurotoxin type A for cosmetic applications

Very few pharmaceutical preparations share an evolutionary history as remarkable as that of botulinum neurotoxin (BoNT). The exotoxin of the organism Clostridium botulinum, once feared as a terrible poison, has been reborn as a highly regarded and widely used therapeutic and aesthetic agent. In less than two decades since the report of the success of BoNT type A (BoNTA) in reducing glabellar lines, injection of this product has become the most common non‐surgical cosmetic procedure performed in the USA and worldwide. In addition to temporarily eliminating rhytids by muscle weakening, other dermatologic applications of BoNTA include correcting facial asymmetries and treating hyperhidrosis. Although BOTOX is the most clinically substantiated and published of the BoNTA preparations, other BoNTA products, as well as a BoNT type B product, are available in some parts of the world, and others are in development.